News
CDNA
19.25
+4.34%
0.80
Weekly Report: what happened at CDNA last week (0630-0704)?
Weekly Report · 1d ago
CareDx’s HeartCare Study: A Game Changer in Transplant Monitoring?
TipRanks · 5d ago
CareDx’s ALAMO Study: A Game Changer in Lung Transplant Surveillance?
TipRanks · 5d ago
CareDx’s ALAMO Study: A New Era in Lung Transplant Surveillance
TipRanks · 07/01 16:03
CareDx’s HeartCare Study: A Game-Changer in Transplant Surveillance?
TipRanks · 07/01 16:01
Weekly Report: what happened at CDNA last week (0623-0627)?
Weekly Report · 06/30 10:59
Weekly Report: what happened at CDNA last week (0616-0620)?
Weekly Report · 06/23 10:52
Natera: Growth Likely To Moderate Despite Signatera Test Medicare Coverage
Seeking Alpha · 06/17 13:41
Weekly Report: what happened at CDNA last week (0609-0613)?
Weekly Report · 06/16 10:58
CareDx: The Transplant Diagnostics Leader, But Challenges Will Increase On The Road Ahead
Seeking Alpha · 06/14 11:23
CareDx Director Makes Significant Stock Sale
TipRanks · 06/14 02:05
CareDx Stockholders Approve Key Proposals at Annual Meeting
TipRanks · 06/12 21:28
Is IDEXX Laboratories Stock Outperforming the Dow?
Barchart · 06/11 06:46
Weekly Report: what happened at CDNA last week (0602-0606)?
Weekly Report · 06/09 10:59
Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026
Seeking Alpha · 06/08 03:36
CareDx Announces New $50 Million Stock Repurchase
TipRanks · 06/03 21:07
CareDx to repurchase 5% of outstanding shares
Seeking Alpha · 06/03 20:40
CareDx authorizes new repurchase of up to $50M of shares
TipRanks · 06/03 20:35
CAREDX INC: AUTHORIZES NEW $50 MLN SHARE REPURCHASE PROGRAM
Reuters · 06/03 20:31
*CareDx: Completed Repurchase of $50M of Stk Representing Approximately 5% of Outstanding Shrs >CDNA
Dow Jones · 06/03 20:31
More
Webull provides a variety of real-time CDNA stock news. You can receive the latest news about Caredx through multiple platforms. This information may help you make smarter investment decisions.
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.